Literature DB >> 11213805

Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model.

L D Notarangelo1, S Giliani, C Mazza, P Mella, G Savoldi, C Rodriguez-Pérez, E Mazzolari, M Fiorini, M Duse, A Plebani, A G Ugazio, M Vihinen, F Candotti, R F Schumacher.   

Abstract

Cytokines play a major role in lymphoid development. Defects of the common gamma chain (gamma(c)) or of the JAK3 protein in humans have been shown to result in a severe combined immune deficiency (SCID), with a profound defect in T and natural killer (NK)-cell development, whereas B-cell generation is apparently unaffected (T-B+NK-SCID). While extensive molecular and biochemical analysis of these patients has been instrumental in understanding better the biological properties of the gamma(c) and JAK3 protein, an unexpected phenotypic heterogeneity of gamma(c) and JAK3 deficiency has emerged, indicating the need for appropriate and extensive investigations even in patients with atypical presentations. At the same time, characterization of the defects has been instrumental in the development of novel therapeutic approaches, from in utero hematopoietic stem cell transplantation to gene therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11213805     DOI: 10.1034/j.1600-065x.2000.17812.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  19 in total

Review 1.  Targeting the Jak/STAT pathway for immunosuppression.

Authors:  J J O'shea
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 2.  Janus kinases to jakinibs: from basic insights to clinical practice.

Authors:  Massimo Gadina; Mimi T Le; Daniella M Schwartz; Olli Silvennoinen; Shingo Nakayamada; Kunihiro Yamaoka; John J O'Shea
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580

Review 3.  Inborn errors of human JAKs and STATs.

Authors:  Jean-Laurent Casanova; Steven M Holland; Luigi D Notarangelo
Journal:  Immunity       Date:  2012-04-20       Impact factor: 31.745

Review 4.  The Development of Next-generation PBMC Humanized Mice for Preclinical Investigation of Cancer Immunotherapeutic Agents.

Authors:  Y Maurice Morillon; Ariana Sabzevari; Jeffrey Schlom; John W Greiner
Journal:  Anticancer Res       Date:  2020-10       Impact factor: 2.480

5.  Matched unrelated bone marrow transplant for severe combined immunodeficiency.

Authors:  Chaim M Roifman; Eyal Grunebaum; Ilan Dalal; Luigi Notarangelo
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

6.  Effect of Janus kinase 3 on the peptide transporters PEPT1 and PEPT2.

Authors:  Jamshed Warsi; Zohreh Hosseinzadeh; Luo Dong; Tatsiana Pakladok; Anja T Umbach; Shefalee K Bhavsar; Ekaterina Shumilina; Florian Lang
Journal:  J Membr Biol       Date:  2013-08-10       Impact factor: 1.843

Review 7.  Laboratory evaluation of primary immunodeficiencies.

Authors:  João B Oliveira; Thomas A Fleisher
Journal:  J Allergy Clin Immunol       Date:  2009-12-29       Impact factor: 10.793

8.  Atypical X-linked SCID phenotype associated with growth hormone hyporesponsiveness.

Authors:  M V Ursini; L Gaetaniello; R Ambrosio; E Matrecano; A J Apicella; M C Salerno; C Pignata
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

9.  JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.

Authors:  Paqui G Traves; Bernard Murray; Federico Campigotto; René Galien; Amy Meng; Julie A Di Paolo
Journal:  Ann Rheum Dis       Date:  2021-03-19       Impact factor: 19.103

Review 10.  Gene therapy for severe combined immunodeficiency: are we there yet?

Authors:  Marina Cavazzana-Calvo; Alain Fischer
Journal:  J Clin Invest       Date:  2007-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.